Listen to the article
The FDA approves higher-dose Wegovy for weight loss, tripling maximum strength
The U.S. Food and Drug Administration has approved a new, higher-dose version of the popular weight loss drug Wegovy, offering a more potent option for adults struggling with obesity. The 7.2 mg dose, marketed as Wegovy HD, represents a significant increase from the previous maximum dose of 2.4 mg.
This marks the fourth approval under the FDA’s National Priority Voucher pilot program, which aims to expedite approvals for treatments addressing critical national health priorities.
“The new FDA is moving with unprecedented efficiency on products that advance national priorities,” said FDA Commissioner Dr. Martin Makary in a press release. “Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.”
The higher-dose GLP-1 receptor agonist is indicated for weight reduction and long-term weight management in adults with obesity or overweight individuals with at least one weight-related condition. According to the FDA, “The approval of a new higher dose will provide adult patients with an additional therapeutic option, offering the potential for greater weight loss.”
Clinical data supporting the approval, granted to Danish pharmaceutical giant Novo Nordisk, demonstrated that higher doses resulted in additional average weight loss compared to previous dosing levels. In the STEP UP clinical trial, patients taking the higher dose experienced an average weight loss of 20.7% compared to approximately 16% on the standard dose. About one-third of participants lost 25% or more of their body weight.
Patients with both obesity and type 2 diabetes saw similar blood sugar reductions with the higher dose compared to lower doses, the agency noted.
The safety profile of Wegovy HD is consistent with known side effects of semaglutide, which commonly include gastrointestinal reactions such as nausea, vomiting, diarrhea, constipation, and abdominal pain. However, skin sensitivity, pain, or burning occurred more frequently with higher doses, though these issues generally resolved on their own or with dose reduction. The FDA continues to investigate these adverse effects.
The agency warned that Wegovy should not be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, a rare inherited genetic disorder. All patients should consult with healthcare providers for guidance on proper use.
Jamey Millar, executive vice president of U.S. operations for Novo Nordisk, expressed enthusiasm for the approval: “We are excited to bring Wegovy HD injection to adults with obesity who are looking for powerful weight loss, as no other weight-loss medicine has been studied to show superiority to Wegovy HD.”
Millar also highlighted that Wegovy has demonstrated reduced risk of cardiovascular events such as stroke, heart attack, or cardiovascular death in patients with known heart disease.
Dr. Peter Balazs, a hormone and weight-loss specialist practicing in New York and New Jersey, provided context on the approval’s significance. “For patients who start on 2.4 mg and then hit a frustrating plateau, or for those with a very high baseline BMI who may need a stronger metabolic push, this creates a legitimate, evidence-based escalation path rather than forcing an early switch to another drug class,” he told Fox News Digital.
However, Balazs cautioned that while this approval gives Novo Nordisk an opportunity to remain competitive on efficacy, he does not expect it to “dramatically reshape the GLP-1 landscape” as the company continues developing next-generation therapies. He noted that other drugs have shown greater efficacy in prior studies, and the broader GLP-1 market is likely to see significant evolution as new molecules enter the market.
The specialist emphasized that the incidences of gastrointestinal and skin-related side effects at this higher dose are “meaningful” and stressed that “this approval is for obesity management, not diabetes treatment.” For patients with type 2 diabetes, currently approved semaglutide dosing remains lower unless the primary treatment goal is weight loss.
This approval comes amid growing interest in GLP-1 medications for weight management, with Novo Nordisk previously announcing plans to reduce the list prices of its popular Wegovy and Ozempic drugs in the U.S. market. The weight loss medication category has experienced unprecedented demand, leading to periodic shortages and increased competition from other pharmaceutical companies developing similar treatments.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
7 Comments
The obesity crisis is a complex issue, and new treatment options are always welcome. However, I wonder if a higher-dose drug is the best long-term solution, or if lifestyle changes and behavioral therapies should still be the primary focus.
From an investment perspective, the approval of this new weight loss drug could be a positive development for relevant pharmaceutical companies and their shareholders. But as always, I’ll need to dive into the details before considering any related investments.
As someone who struggles with weight, I’m cautiously optimistic about this new higher-dose option. The potential for greater weight loss is enticing, but I’ll be looking closely at the clinical data before considering it.
Expedited approvals for drugs addressing critical health priorities is an interesting approach by the FDA. While it’s positive they are moving quickly, I hope they maintain high standards for efficacy and safety.
This approval seems like a step forward in addressing the obesity epidemic, which is a major public health challenge. However, I hope the FDA will closely monitor the drug’s safety profile given the higher dosage.
Agreed. Any new, more potent weight loss drug needs rigorous testing to ensure it is safe and effective for long-term use.
Interesting development in the weight loss drug space. While higher doses can lead to greater weight loss, safety and long-term efficacy will be key considerations. I wonder how this compares to other GLP-1 agonists on the market.